Aminaphthone

DB13039InvestigationalSmall molecule

Aminaphthone is a medication that inhibits erythrocyte aggregation in capillaries, improving venous return for the treatment of capillary fragility. Aminaftone has been investigated for the treatment of Cockett Syndrome, May-Thurner Syndrome, and Iliac Vein Obstruction.

Chemical structure of Aminaphthone
Formula / weight
C18H15NO4 · 309.321 g/mol (avg)
Also known as
Aminaftone · Aminaphtone

Resolves to

Compound
UNII03JLX11PE9CAS14748-94-8ChEBI135317PubChem84621
Clinical / RWD
RxNorm46276
Structure
InChIKeyYLMPBJUYFTWHKJ-UHFFFAOYSA-NSMILESCC1=C(OC(=O)C2=CC=C(N)C=C2)C(O)=C2C=CC=CC2=C1O

What you can answer from here — as of April 02, 2025

1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
2ContraindicationsEach with its own population and attribute set
Sign in
3Marketed productsAcross 1 country and 3 labellers
Sign in

Which other approved drugs treat the same conditions as Aminaphthone, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In